Literature DB >> 18984481

Prophylactic immunisation against traveller's diarrhoea caused by enterotoxin-forming strains of Escherichia coli and against cholera: does it make sense and for whom?

T Weinke1, I Liebold, G D Burchard, N Frühwein, M P Grobusch, C Hatz, H Kollaritsch, H D Nothdurft, E Reisinger, B Rieke, Ch Schönfeld, R Steffen, A Stich.   

Abstract

Traveller's diarrhoea (TD) constitutes the most common disease relevant to travel medicine with ETEC as the leading causative pathogen. Cholera is the most serious, but very rare form of TD. ETEC and cholera share pathogenic mechanisms by producing a toxin that has an 80% amino acid homology. A consensus of German-speaking experts sees the indication to use the whole cell/B subunit oral cholera vaccine (WC--BS) if cholera is a risk for aid workers or travellers with an anticipated threat of cholera who stay under poor hygienic conditions. The use of the vaccine should be considered in the indication to avoid ETEC TD for travellers with predisposing illness or medication or for travellers at risk to develop a serious course.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18984481     DOI: 10.1016/j.tmaid.2006.05.003

Source DB:  PubMed          Journal:  Travel Med Infect Dis        ISSN: 1477-8939            Impact factor:   6.211


  4 in total

Review 1.  Travellers' diarrhoea - pros and cons of different prophylactic measures.

Authors:  Angelika Wagner; Ursula Wiedermann
Journal:  Wien Klin Wochenschr       Date:  2009-10       Impact factor: 1.704

2.  Vaccination strategies to combat an infectious globe: oral cholera vaccines.

Authors:  Rosa M López-Gigosos; Elena Plaza; Rosa M Díez-Díaz; Maria J Calvo
Journal:  J Glob Infect Dis       Date:  2011-01

3.  Immunogenicity of cholera vaccination in children with inflammatory bowel disease.

Authors:  Łukasz Dembiński; Anna Stelmaszczyk-Emmel; Katarzyna Sznurkowska; Agnieszka Szlagatys-Sidorkiewicz; Andrzej Radzikowski; Aleksandra Banaszkiewicz
Journal:  Hum Vaccin Immunother       Date:  2021-04-01       Impact factor: 3.452

4.  Effectiveness and economic analysis of the whole cell/recombinant B subunit (WC/rbs) inactivated oral cholera vaccine in the prevention of traveller's diarrhoea.

Authors:  Rosa López-Gigosos; Pedro Garcia-Fortea; Maria J Calvo; Emilia Reina; Rosa Diez-Diaz; Elena Plaza
Journal:  BMC Infect Dis       Date:  2009-05-16       Impact factor: 3.090

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.